Eli Lilly loses patent lawsuit for Strattera

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera.

The U.S. District Court for the District of New Jersey ruled against the company, saying its method-of-use patent for the drug is invalid.

Strattera last year generated $609 million in revenue, about 3 percent of Lilly's total. The patent had been set to expire in May 2017.

The drugmaker said it plans to appeal the ruling, but noted that it now faces the prospects of potentially having to compete with a generic version of the drug.

"Assuming a launch of a generic version of Strattera in the U.S., the loss of revenue will undoubtedly add to the challenges we will face during upcoming patent expirations on other key products," said John Lechleiter, the company's chairman and chief executive.

As a result, the company said it now expects revenue growth this year to be in the low to mid-single digits. It previously anticipated revenue to grow in the mid-single digits.

It also plans to lower its costs by at least $1 billion by the end of next year and reduce its full-time work force.

Lilly has announced more than 2,000 job cuts toward its goal of 5,500 cuts, which the company set in September.

Due to those measures, the company expects it will generate enough cash in the coming years to fund research and development and make other necessary investments, Lechleiter said.

"In addition, we do not intend to deviate from our plan to maintain our dividend at least at its current level," he added.

The ruling on Strattera is the latest court setback for Eli Lilly in recent weeks.

Last month, the U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that a patent on its cancer drug Gemzar is invalid. The drug is set to lose patent exclusivity on Nov. 15.

The company is still waiting a court decision on its osteoporosis drug Evista. And a patent trial on the cancer drug Alimta is set to start on Nov. 8.

Lilly’s lack of new medicines to replace best-selling drugs Zyprexa and Cymbalta, which will lose their patent protection in 2011 and 2013, respectively, has spooked investors.

Eli Lilly shares fell 88 cents, or 2.4 percent, to $35.72 in aftermarket trading after slipping 11 cents to $36.60 during the regular session.


  • Consumers and governments should be more skeptical of big Pharma inflated costs
    Consumers and governments should be more skeptical of big Pharma inflated costs claims when it comes to the development of new drugs, says a report published in the London School of Economics health industry journal BioSocieties. The journal article is available for detailed reading here.

    The 17-page report, â??Demythologizing the High Costs of Pharmaceutical Researchâ??, was written by Rebecca Warburton, associate professor in the School of Public Administration at the University of Victoria and Donald Light, professor in comparative health-care at the University of New Jersey and a visiting professor at Standford University.

    Research and development costs of a new drug can range from virtually nothing to being very expensive, claims the study and explains that the pharmaceutical industry cites figures based on work by economists at a U.S. centre, which has received substantial funding from Big Pharma industry figures when it claims research and development costs in the billions of dollars to launch new drugs to the marketplace.

    The entire study is an interesting read because it breaks down the leading reason that the big pharmaceutical companies use to justify Americans having the highest prescription drug costs in the world, and show that they often widely over estimate the cost of R&D and use it to excuse their gouging of American drug buyers.

  • mdenny
    I am a parent of 2 kids on Strattera, totally unable to take Ritalin (cheapest) ADHD med. One month dosage of Strattera for 1 child is just short of $500. However if I were in Canada, Europe anywhere but the US, the same drug would be pennies on the dollar. Yes I want research into new meds, however I don't want to be the sole source of the funding. You need to get your brain cells asparkin' and consider the possibility that this might actually benefit you.....as well as the new changes in the health care laws....THINK, think, think.......
  • Crucify the successful a little more...
    Before you think how great it is that these "rich" drug companies are having their patents ripped out from under them, be sure to realize this: The generics don't spend the billions of dollars that Lilly, Roche, Pfizer, etc., do on research. So if you think this court ruling is good, pray that your parents, spouse, or other loved ones never get Alzheimer's Disease because the drug companies have already had to cut their investment into finding cures for it and many other diseases. This will only be magnified if the Constitutionally illegal ObamaCare makes it past the courts.

    Post a comment to this story

    We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
    You are legally responsible for what you post and your anonymity is not guaranteed.
    Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
    No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
    We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

    Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

    Sponsored by

    facebook - twitter on Facebook & Twitter

    Follow on TwitterFollow IBJ on Facebook:
    Follow on TwitterFollow IBJ's Tweets on these topics:
    thisissue1-092914.jpg 092914

    Subscribe to IBJ